Featured Research

from universities, journals, and other organizations

Newly Refined Antibody Therapy May Be Potent Treatment For Autoimmune Diseases

Date:
April 30, 2008
Source:
Rockefeller University
Summary:
An old, fickle therapy for a variety of autoimmune diseases is getting a makeover, thanks to a decade-long investigation. The original treatment, called intravenous immunoglobulin or IVIG, is an amalgam of specific antibodies made from the pooled blood plasma of thousands of healthy donors. Physicians have used it both on-label and off in patients with lupus, arthritis, asthma and other immune disorders, to varying degrees of success. But new research shows that understanding how the therapy works at a molecular level can help researchers create a version in the lab that's many times more potent.

An old, fickle therapy for a variety of autoimmune diseases is getting a makeover, thanks to a decade-long investigation by Rockefeller University researchers. The original treatment, called intravenous immunoglobulin or IVIG, is an amalgam of specific antibodies made from the pooled blood plasma of thousands of healthy donors.
Credit: Image courtesy of Rockefeller University

An old, fickle therapy for a variety of autoimmune diseases is getting a makeover, thanks to a decade-long investigation by Rockefeller University researchers. The original treatment, called intravenous immunoglobulin or IVIG, is an amalgam of specific antibodies made from the pooled blood plasma of thousands of healthy donors. Physicians have used it both on-label and off in patients with lupus, arthritis, asthma and other immune disorders, to varying degrees of success. But new research shows that understanding how the therapy works at a molecular level can help researchers create a version in the lab that’s many times more potent.

Jeffrey Ravetch, Theresa and Eugene M. Lang Professor and head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology, has been interested in IVIG ever since he became aware of its inherent paradox: IgG antibodies, the very class of antibodies that triggers autoimmune diseases, give IVIG its anti-inflammatory properties when pooled from healthy donors. In 2006, Ravetch and his colleagues discovered that this apparent contradiction could be attributed to a single sugar molecule called sialic acid, located at the very tip of some IgG antibodies. When present, the molecule confers anti-inflammatory properties. When absent, the IgG molecules lose their protective abilities and can actually cause inflammation.

Once the scientists had pinned down the molecular mechanism at the source of the contradiction and proved that they could map out a strategy for building a drug with the therapeutic properties of IVIG, they set about creating it. Ravetch, together with his collaborators at the University of New Hampshire and The Scripps Research Institute, produced an engineered, sialylated IgG molecule that — when given to arthritic mice — was about 30 times more effective than IVIG alone. “This paper provides a clear route for developing an alternative for IVIG, which could be of great benefit to patients with autoimmune diseases,” Ravetch says. The results, reported in the latest issue of Science, also describe the precise structural requirements needed to create IgG with protective properties.

Rockefeller has licensed the technology to the biotechnology company Centaurus Pharmaceuticals, which is working to create a product that can be used in clinical trials. Ravetch believes that the resulting drug will have the potential to provide relief to people with a wide range of ailments, including those for whom IVIG just barely scratches the surface. In lupus, for instance, the current preparation has such low activity that the amount required to effect a noticeable difference exceeds the amount that can be realistically derived from the blood supply. “But with the recombinant form,” Ravetch says, “you can make an unlimited, potent supply.”

Journal reference: Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc. Science 320 (5874): 373–376 (April 18, 2008)


Story Source:

The above story is based on materials provided by Rockefeller University. Note: Materials may be edited for content and length.


Cite This Page:

Rockefeller University. "Newly Refined Antibody Therapy May Be Potent Treatment For Autoimmune Diseases." ScienceDaily. ScienceDaily, 30 April 2008. <www.sciencedaily.com/releases/2008/04/080428145012.htm>.
Rockefeller University. (2008, April 30). Newly Refined Antibody Therapy May Be Potent Treatment For Autoimmune Diseases. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2008/04/080428145012.htm
Rockefeller University. "Newly Refined Antibody Therapy May Be Potent Treatment For Autoimmune Diseases." ScienceDaily. www.sciencedaily.com/releases/2008/04/080428145012.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins